Key result
Abciximab infusion post-angioplasty induced a drastic fall in platelet count from 200,000 to 3,000 per cm in a 68-year-old female, which resolved after stopping the drug and transfusing platelets.
Why the study?
Abciximab can cause bleeding and thrombocytopenia, but very few cases have been reported from India.
Case Report (n=1)
Abciximab use during percutaneous coronary intervention can induce severe, rapid-onset thrombocytopenia requiring prompt cessation and platelet transfusion.
Prompts platelet monitoring with abciximab; single case leaves open incidence and risk factors.
Abciximab is a humanized monoclonal antibody which acts against αIIbβ3 receptor. The use of abciximab with percutaneous coronary interventions (PCI) has proven good results in patients. The drug has been notorious to cause bleeding and also decrease in the number of platelets. In this case the patient had normal platelet count but the count decreased significantly after abciximab was given. A number of cases have been reported but very few have been reported from India. Hence, we found it important to report and it is a valuable asset for scientific research.
No takes yet. Share an insight, caveat, or question.
Sen et al. (2022) conducted a case report in ST elevation inferior wall myocardial infarction (n=1). Abciximab was evaluated on Severe thrombocytopenia (platelet count). Abciximab infusion post-angioplasty induced a drastic fall in platelet count from 200,000 to 3,000 per cm in a 68-year-old female, which resolved after stopping the drug and transfusing platelets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: